News

­

Quark Pharmaceuticals to Present Keynote Address at IBC’s 18th Annual TIDES Oligonucleotide and Peptide Therapeutics Conference

May 9th, 2016|

FREMONT, Calif., May 9, 2016  — Quark Pharmaceuticals, Inc. (“Quark”) today announced a keynote address on the company’s history of oligonucleotide development will be presented at the 18TH Annual TIDES Oligonucleotide and Peptide Therapeutics Conference at 11 a.m. PDT on May 10 at the Long Beach Convention Center in Long Beach, CA. Daniel Zurr, Ph.D., […]

Transplant Genomics® and Quark Pharmaceuticals Announce Discovery and Development Collaboration

April 14th, 2016|

Pleasanton, CA, and San Francisco, CA, April 14, 2016 – Transplant Genomics Inc. (“TGI”) and Quark Pharmaceuticals, Inc. (“Quark”) today announced their joint intent to pursue a discovery and development collaboration involving the use of TGI’s TruGraf™ blood test in a Phase 3 clinical trial involving patients being treated for delayed graft function (DGF) with […]

Quark Pharmaceuticals Doses First Patients in Two Pivotal Phase III Studies and One Phase II Study of RNAi-Based Therapeutics for Kidney and Eye Indications

March 14th, 2016|

Clinical Advances with Treatments for Delayed Graft Function (DGF), Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) and Acute Kidney Injury (AKI) Catapult Quark Into Front Line of siRNA Companies

FREMONT, Calif., March 14, 2016 /PRNewswire/ — Quark Pharmaceuticals Inc., a late clinical-stage pharmaceutical company and leader in the discovery and development of novel RNA interference (RNAi)-based therapeutics, […]

Quark announces issue of U.S. patent for novel treatment of lung transplantation associated injury

December 9th, 2015|

U.S. Patent No. 9,205,100, issued on December 8, 2015, relates to a novel method for treatment of lung disease or lung injury which is associated with lung transplantation. The patented method uses a proprietary combination of nucleic-acid inhibitors targeting two types of toll-like receptors, namely TLR2 and TLR4. Quark demonstrated that this novel inhibitor combination […]

Quark Announces Initiation of Patient Recruitment for Global Pivotal Study of QPI-1007 in NAION

October 27th, 2015|

Fremont, Ca – October 27, 2015– Quark Pharmaceuticals, Inc, a late clinical-stage pharmaceutical company, who is a leader in the discovery and development of novel RNA interference (RNAi)-based therapeutics, announced today that it has initiated the U.S. arm of a global Phase II/III pivotal study (NCT02341560) of QPI-1007 for treatment of acute non arteritic anterior […]

Quark announces patent approval for Methods for treating eye disorders

September 1st, 2015|

The present invention relates to compositions and methods for inhibiting loss of a retinal ganglion cell in a subject, comprising non-invasively applying to the surface of the eye of the subject an ophthalmic composition comprising a therapeutically effective amount of at least one siRNA which down regulates expression of a target gene associated with loss […]

Quark will present at Eurotides 2015, Maritim proArte Hotel, Berlin, Germany ,16-18 Nov 2015

August 23rd, 2015|

http://www.informa-ls.com/event/eurotides2015

Quark announces patent approval for Compositions and methods for treatment of ear disorders

July 28th, 2015|

The present invention relates to pharmaceutical compositions useful for topical, non-invasive delivery of an oligonucleotide to the ear and to methods for the treatment of an ear disorder, including hearing loss arising from chemical-induced ototoxicity, acoustic trauma and presbycusis; and microbial infections. The method comprises topically administering to the ear of a subject in need […]

Quark announces patent approval for therapeutic uses of inhibitors of RTP801

June 16th, 2015|

The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases respiratory conditions and hearing disorders based upon inhibition of the RTP801 gene and/or protein.

Read More…

Quark announces patent approval for double stranded RNA compounds to RhoA and use thereof

June 2nd, 2015|

The present invention relates to compounds, pharmaceutical compositions comprising same, methods of use thereof and kits for the down-regulation of RhoA gene. The compounds, compositions, methods and kits are useful in the treatment of subjects suffering from diseases or conditions and or symptoms associated with diseases or conditions in which RhoA expression has adverse consequences […]